PM577a Begins First Human In Vivo Prime Editing Study
Prime Medicine dosed the first participant in its global Phase 1/2 study of PM577a, an LNP-delivered prime editor designed to correct ATP7B p.H1069Q in hepatocytes. This is a meaningful execution milestone for in vivo…
